Artelo Biosciences (ARTL) announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol and tetramethylpyrazine. The findings were presented by Professor Saoirse O’Sullivan, Vice President of Translational Science at Artelo Biosciences, at the International Medical Cannabis Conference, held February 13-14, 2025, at the University of Bern, Switzerland. Professor O’Sullivan’s presentation, “A Cannabidiol Cocrystal Tablet Has Comparable Pharmacokinetics to Epidiolex,” highlighted results from canine studies evaluating Artelo’s oral solid formulations of ART12.11 against the liquid formulation of Epidiolex, the only FDA-approved CBD therapy. The studies showed that two different tablet formulations of ART12.11 achieved CBD and metabolite exposure levels similar or greater to the equivalent dose of Epidiolex, supporting the potential of ART12.11 as an alternative formulation of CBD.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL: